The Latest in News

British good practice paper offers MCL diagnosis pearls

June 15, 2018

Aggressive Lymphomas

FDA approves pembrolizumab for relapsed/refractory PMBCL

June 14, 2018

Aggressive Lymphomas

FDA grants regular approval to venetoclax for CLL/SLL

June 8, 2018

Indolent Lymphoma

Overcoming TP53 mutation proves difficult in MCL

June 1, 2018

Aggressive Lymphomas

Older CLL and NHL patients are more vulnerable to toxicities

May 23, 2018

Indolent Lymphoma

Physical inactivity linked to lymphoma risk

May 18, 2018

Indolent Lymphoma

Adding bortezomib does not improve MCL outcomes

May 16, 2018

Aggressive Lymphomas

Study: No link between non-Hodgkin lymphoma and Q fever

May 15, 2018

Aggressive Lymphomas

5-year data show deepening response with ibrutinib in CLL

May 11, 2018

Indolent Lymphoma

In young MCL patients, optimal treatment may vary

May 4, 2018

Indolent Lymphoma

Novartis CAR T-cell therapy adds a lymphoma indication

May 3, 2018

Aggressive Lymphomas

Five-year survival for non-Hodgkin lymphoma tops 71%

May 2, 2018

Aggressive Lymphomas

FDA places partial hold on trials after secondary lymphoma

April 25, 2018

Aggressive Lymphomas

Venetoclax shows muscle against CLL relapsed after idelalisib

April 18, 2018

Indolent Lymphoma

PDPK1 could be novel target in MCL

April 13, 2018

Aggressive Lymphomas